Shifting the focus from organ to biomarker has unlocked new options for rare and advanced cancers. Uneven efficacy, diagnostic access, and regulation still slow clinical rollout.

Douglas Grossman, MD, Ph.D., co-leader of the Melanoma Center at Huntsman Cancer Institute at the University of Utah (the U) ...

Cancer diagnoses traditionally require invasive or labor-intensive procedures such as tissue biopsies. Researchers at the Ludwig-Maximilians-Universität München (LMU) have now reported on a method ...

Cancer’s deadliest talent is not rapid growth but the ability to sidestep the internal programs that should make damaged cells self-destruct. Across multiple labs, researchers are now converging on a ...

Academia Sinica and National Taiwan University (NTU) Hospital have jointly developed PanMETAI, an AI metabolomics platform to detect the early stages of pancreatic cancer. The tabular AI model detects ...

NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.

Research has uncovered a surprising biological twist: molecules that help support healthy aging can also contribute to cancer growth.

A fleeting DNA fold called i‑DNA can switch cancer‑related genes on and off, revealing a hidden structural weak point that ...

Cells constantly monitor and recycle their proteins through a tightly regulated waste-disposal system. Proteins that are no ...

A newly discovered link between pancreatic cancer and neural signaling reveals a promising drug target that slows tumor ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Fuh is an ...